Abstract | OBJECTIVES: RESULTS: DISCUSSION: The current body of evidence is insufficient to support the use of intranasal ketamine over other standard therapies for acute pain. However, current evidence can be used when developing dosing strategies, preparing for adverse reactions, and generating hypotheses for future, more robust research.
|
Authors | Robert J Rocchio, Kristina E Ward |
Journal | The Clinical journal of pain
(Clin J Pain)
Vol. 37
Issue 4
Pg. 295-300
(04 01 2021)
ISSN: 1536-5409 [Electronic] United States |
PMID | 33555694
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. |
Chemical References |
- Analgesics
- Analgesics, Opioid
- Ketamine
|
Topics |
- Acute Pain
(drug therapy)
- Administration, Intranasal
- Analgesics
- Analgesics, Opioid
- Child
- Double-Blind Method
- Humans
- Ketamine
(administration & dosage)
- Pain Measurement
|